Home›Earnings›Results›Abbott Q2 results lift margins and EPS outlook after E…

Abbott Q2 results lift margins and EPS outlook after Exact Sciences deal

Abbott posted 13% reported growth, 4.8% organic growth, and adjusted EPS of $1.31 that beat analysts by 235 basis points, while narrowing and lifting its full-year earnings guidance range.

Reported · Written up by our desk · Results

Abbott Laboratories said its Q2 earnings show the Exact Sciences acquisition is working as expected, helping ease prior worries about near-term margin pressure and execution risk, MarketBeat Ratings reports.

The company reported 13% growth and 4.8% organic growth. Strength was driven by Exact Sciences, including a 42.3% jump in diagnostic services, alongside gains in established pharmaceuticals and medical devices, while nutrition declined 3.1%.

Margins were the key catalyst, with contractions coming in smaller than expected, leaving gross margin, operating income, and net income above analysts forecasts. Abbott delivered adjusted earnings per share of $1.31, beating expectations by 235 basis points.

For guidance, Abbott maintained its forecast for organic revenue growth, but improved its outlook for earnings by lifting the midpoint and narrowing the full-year range. The company framed the back half of 2026 as a period where profitability metrics have improved, supporting stronger sentiment and a rebound in its share price following the release.

More like this

Sources